Infusion Pumps Accessories Market: as the accessories and consumables segment accounting for approximately 53% of the combined global infusion pumps and accessories market with over 90% of US hospitalised patients receiving IV medicines via infusion pump confirms the fundamental recurring revenue model of single-use infusion accessories, B. Braun Medical announcing the first US NRFit connector conversion at a Midwest children’s hospital in July 2024 and receiving FDA 510(k) clearance for Introcan Safety 2 Deep Access IV Catheter in September 2024 defines the patient safety technology refresh direction, so ICU Medical Clave receiving new FDA-cleared CLABSI-reduction labeling and BD completing the USD 4.20 Billion Edwards Lifesciences Critical Care acquisition on September 3 2024 confirm the clinical and commercial consolidation trajectory that sustains 5.9% CAGR through 2035.

The global infusion pumps accessories market size was USD 10.88 Billion in 2025 and is expected to register a revenue CAGR of 5.9% during the forecast period. Market revenue growth is driven by factors such as the large and stable recurring consumption base of single-use IV administration accessories requiring replacement with every patient care episode to maintain infection control protocols across hospital, ambulatory, and home care infusion settings, growing hospital IV therapy procedure volumes for oncology, critical care, parenteral nutrition, and anti-infective indications, and as well as patient safety-driven technology transitions including NRFit ISO 80369-6 small-bore connector adoption and needleless connector clinical differentiation that are shifting accessory procurement from commodity price competition to clinically validated infection prevention platform decisions. The first driving factor is the scale of recurring single-use infusion accessory consumption, with over 90% of US hospitalised patients receiving IV medicines per Wolters Kluwer Health published data, and the accessories and consumables segment accounting for approximately 53% of the combined infusion pumps and accessories market by revenue in 2024, confirming that IV administration sets, peripheral IV catheters, tubing, needleless connectors, and extension sets generate more annual revenue than the infusion pump capital hardware through mandatory per-episode replacement at every IV therapy patient encounter. IV administration sets work by providing the physical fluid pathway from IV solution container through an infusion pump mechanism to the patient’s IV access site, with single-use sets replaced according to hospital infection control protocols at intervals ranging from 24 hours to 96 hours per set depending on the medication and CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections recommendation for the specific IV therapy type. On 3 September 2024, BD, which is Becton Dickinson and Company, completed its acquisition of Edwards Lifesciences’ Critical Care product group for USD 4.20 Billion, renaming it BD Advanced Patient Monitoring, integrating hemodynamic monitoring with BD Alaris infusion accessories and confirming BD’s commitment to expanding its integrated infusion accessories and monitoring platform for closed-loop IV fluid and medication delivery in operating rooms and ICUs globally. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way patient safety technology transitions including NRFit ISO 80369-6 small-bore connector mandates and needleless connector clinical differentiation based on infection prevention evidence are shifting IV accessory procurement from commodity price competition at hospital GPO level toward formulary-level clinical decisions anchored in patient harm prevention standards, which allows premium safety accessory products to command price premiums that sustain revenue growth above the underlying IV procedure volume growth rate. Once a hospital system adopts an NRFit connector mandate as a patient safety policy, the entire neuraxial anaesthesia and epidural infusion accessory inventory must convert simultaneously to NRFit-compatible syringes, catheters, and connectors, generating a capital-independent procurement cycle driven by compliance deadlines rather than capital replacement schedules. ICU Medical Clave’s new FDA-cleared labeling demonstrating significantly greater infection reduction and cost savings versus non-Clave hospitals provides a regulatory agency-validated infection prevention superiority claim that hospital value analysis committees can reference to support Clave formulary inclusion above competing needleless connector brands. As a result, demand and revenue share are concentrating around the accessory platforms with the strongest patient safety evidence bases, the broadest hospital formulary positioning, and the deepest pump compatibility integration, and the forecast tilts toward these clinical evidence and compatibility-anchored platforms rather than commodity accessory suppliers competing on unit price alone. For instance, in November 2024, ICU Medical and Otsuka Pharmaceutical Factory announced a joint venture to strengthen IV solutions manufacturing in the North American market, one of several integration events shaping the infusion accessories commercial landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the structural recurring revenue characteristic of single-use infusion accessories that requires replacement at every IV therapy patient encounter regardless of whether the infusion pump hardware has been replaced or upgraded in the capital procurement cycle, creating a per-patient daily accessory consumption volume that compounds directly with hospital census growth and IV therapy intensity independent of capital equipment replacement cycles. Recurring accessory demand works commercially because the CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections specify IV administration set replacement intervals ranging from every 24 hours for blood products and lipid emulsions to every 96 hours for standard administration, creating a mandatory per-episode set replacement framework that hospital infection control programmes must follow as a patient safety compliance requirement, not a discretionary supply choice. Over 90% of US hospitalised patients receive IV medicines per Wolters Kluwer Health data, confirming that nearly every hospital patient generates infusion accessory consumption across every admission day. The accessories and consumables segment of the combined infusion pump and accessories market accounts for approximately 53% of total market revenue in 2024, demonstrating that IV administration sets, needleless connectors, peripheral IV catheters, and extension sets collectively generate more revenue than the capital pump hardware that delivers the medication through them. BD confirmed low single-digit organic growth in Medication Delivery Solutions and mid single-digit organic growth in Medication Management Solutions in Q2 FY2025, reflecting the stable above-GDP recurring revenue growth profile of the infusion accessories category at the largest global IV accessory manufacturer. In October 2024, B. Braun Medical announced plans to increase IV saline fluids production by 20% at its Irvine, California and Daytona Beach, Florida facilities, confirming investment in IV fluid manufacturing capacity that directly drives parallel demand for IV administration set accessories. These are some of the key factors driving revenue growth of the market.

The second driver is the patient safety technology transition shifting IV accessory procurement from commodity price competition at hospital GPO level toward clinically validated infection prevention platform decisions anchored in FDA-cleared safety performance claims, because the NRFit ISO 80369-6 mandated connector incompatibility and the ICU Medical Clave FDA-cleared CLABSI superiority labeling both create hospital institutional obligations that protect premium safety accessory procurement from commodity price comparison. Safety technology transitions work commercially because the ISO 80369-6 NRFit standard physically prevents neuraxial-IV misconnection through an incompatible connection geometry that makes it mechanically impossible to accidentally connect a spinal or epidural syringe to an IV line, addressing a category of fatal medication error documented in neurosurgery, obstetric anaesthesia, and paediatric ICU settings globally. B. Braun Medical announced in July 2024 the first US conversion to NRFit connectors at a Midwest children’s hospital, confirming the clinical inflection point that typically drives accelerated US NRFit adoption across other children’s hospitals before spillover into adult neurosurgery and obstetric units. B. Braun received FDA 510(k) clearance in September 2024 for the Introcan Safety 2 Deep Access IV Catheter with improved dwell times and advanced safety features for peripheral IV insertion in patients with difficult vascular access, expanding the clinical utility of peripheral IV catheters at hospital accounts managing obese, dehydrated, or repeat IV access patients. ICU Medical announced that Clave needlefree IV connectors received new FDA 510(k) labeling clearance with peer-reviewed evidence showing hospitals standardising on Clave achieve significantly greater infection reduction and cost savings versus non-Clave hospitals, providing a regulatory agency reference for hospital value analysis committee formulary decisions. These are some of the key factors driving revenue growth of the market.

Over 90% of US hospitalised patients receive IV medicines via infusion pump per Wolters Kluwer Health data. The accessories and consumables segment accounts for approximately 53% of the combined infusion pump and accessories market revenue in 2024. IV administration sets, peripheral IV catheters, needleless connectors, and extension sets collectively generate more annual revenue than the infusion pump capital hardware itself through mandatory per-episode single-use replacement driven by CDC infection control protocols and hospital patient safety compliance requirements, creating a recurring revenue base that is structurally independent of pump capital replacement cycles.

The third driver is the strategic consolidation of infusion accessories supply with complementary hemodynamic monitoring, IV solutions manufacturing, and pump software capabilities that creates integrated IV therapy platform vendors above the standalone IV accessory supplier level, because hospital supply chain consolidation preferences toward fewer integrated vendor relationships accelerate market share concentration at the platform level above commodity-priced single-product accessory suppliers. Platform integration works commercially because a hospital supply chain director who contracts with BD for BD Alaris infusion pump accessories, BD Advanced Patient Monitoring hemodynamic monitoring, and BD Nexiva peripheral IV catheters in a single vendor relationship achieves procurement administrative simplification, volume discount leverage, and clinical integration coordination that independent accessory supplier alternatives cannot match. BD completed its acquisition of Edwards Lifesciences’ Critical Care division for USD 4.20 Billion on September 3 2024, per the Edwards Lifesciences SEC 8-K filed on that date, with BD confirming APM revenue contribution in Q2 FY2025 results and integrating the hemodynamic monitoring capability with BD Alaris administration set accessories and BD medical devices for closed-loop IV fluid management. ICU Medical and Otsuka Pharmaceutical Factory announced a joint venture in November 2024 to strengthen IV solutions manufacturing and innovation in the North American market, linking ICU Medical’s Clave needleless connector and CADD ambulatory pump accessories supply chain with IV solution manufacturing capacity. These are some of the key factors driving revenue growth of the market.

However, the infusion pumps accessories market faces adoption constraints from price compression on commodity IV administration sets in hospital GPO bulk procurement contracts, single-use PVC medical plastic waste regulatory pressure in European markets, and proprietary pump-accessory compatibility locking reducing inter-brand substitution flexibility. Iran-US sanctions following the United States-Iran confrontation escalation in late February 2026 created plasticiser-grade PVC resin and non-DEHP plasticiser supply uncertainty for IV administration set manufacturers sourcing medical polymer compound and polyurethane tubing intermediates through Strait of Hormuz logistics corridors, adding manufacturing input cost volatility and lead time pressure through Q1 and Q2 2026. Hospital supply chain consolidation toward fewer GPO-contracted supplier relationships concentrates IV accessory purchasing power with large integrated suppliers, reducing the commercial viability of smaller accessory manufacturers competing outside major GPO contract frameworks and compressing margins even for market-leading accessory brands in annual GPO renegotiation cycles. These factors substantially limit infusion pumps accessories market growth over the forecast period.

Based on product type, the global infusion pumps accessories market is segmented into IV administration sets and tubing, peripheral IV catheters and cannulas, needleless and needlefree connectors, extension sets and stop-cocks, IV filters and anti-reflux valves, and ambulatory pump cassettes and specialty accessories. IV administration sets and primary tubing account for the largest revenue share at approximately 38% of 2025 accessories market revenue through their fundamental role as the physical connection between the infusion pump and the patient’s IV access for every IV medication and fluid delivery episode, requiring mandatory single-use replacement under CDC infusion control guidelines. Needleless connectors are expected to register the fastest revenue growth rate in the global accessories market over the forecast period, driven by ICU Medical Clave FDA-cleared CLABSI-reduction superiority labeling, B. Braun NRFit conversion driving new connector specification procurement across neuraxial anaesthesia applications, and growing adoption of closed-system transfer device connectors in oncology IV drug compounding.

Based on end-use, the global infusion pumps accessories market is segmented into hospitals and ICUs, home infusion and ambulatory care centres, and long-term care and hospice settings. Hospitals and ICUs account for the dominant revenue share at approximately 52% of 2025 accessories market revenue through the highest IV therapy density per patient per day of any care setting, driven by critical care vasopressor and sedation IV infusions, surgical perioperative IV fluid management, oncology chemotherapy at hospital day infusion units, and parenteral nutrition for post-operative and chronically ill patients. Home infusion and ambulatory care is expected to register the fastest growth rate in the global accessories market, driven by outpatient oncology infusion programme expansion, home parenteral nutrition therapy for gastrointestinal patients, and outpatient IV anti-infective therapy programmes reducing hospital admission duration for patients with complex infection treatment regimens.

Based on regional analysis, the infusion pumps accessories market in North America accounted for largest revenue share in 2025 at approximately 43% of global revenue. BD Medical MDS and MMS segments, B. Braun IV administration sets and Introcan Safety catheters, and ICU Medical Clave needleless connector formulary dominance at US hospital accounts collectively anchor North American accessories market leadership. Over 90% of US hospitalised patients receive IV medicines via infusion pump per Wolters Kluwer Health, confirming the fundamental per-patient accessory consumption base. B. Braun’s 20% IV saline production capacity expansion at Irvine and Daytona Beach in October 2024 confirms North American IV fluid supply chain capacity investment that directly sustains IV administration set accessory demand. The Iran-US confrontation escalation through Q1 and Q2 2026 creates PVC resin supply cost uncertainty for North American IV administration set manufacturers, though domestic US PVC and polyurethane production capacity provides partial supply chain resilience above import-dependent manufacturers.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and the Netherlands represent the four largest national infusion accessories markets. EU sustainability and medical device circular economy regulatory frameworks in Germany, France, and the Netherlands create growing pressure on IV bag PVC plastic waste, driving investment in recyclable packaging and reduced-plastic IV bag designs. B. Braun’s European headquarters and manufacturing presence in Melsungen, Germany anchors its strong European IV administration set and peripheral IV catheter accessories market position. NRFit ISO 80369-6 connector adoption in European hospital anaesthesiology departments has advanced further than in North America, driven by Joint Commission International Sentinel Event Alerts on neuraxial misconnection errors that preceded the US adoption timeline.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. China, Japan, South Korea, India, and Australia represent the five largest national infusion accessories markets. China has the world’s largest domestic IV administration set manufacturing base concentrated in Zhejiang and Jiangsu provinces, producing cost-competitive commodity infusion sets and peripheral catheters at scale for domestic hospital procurement and export to emerging markets. Growing hospital oncology and critical care capacity in China and India drives expanding per-patient IV accessory consumption volume. Japan’s established high-quality nursing standards sustain premium-tier IV catheter and connector procurement at Japanese tertiary hospital accounts.

The markets in Latin America and Middle East and Africa are expected to register moderate revenue growth rates over the forecast period. Brazil and Mexico represent primary LatAm commercial markets. GCC hospital expansion drives IV administration set and peripheral IV catheter procurement for new acute care and ICU facilities under Saudi Vision 2030 and UAE health infrastructure investment programmes.